Abstract

Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research. The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.

Author affiliations

1. M. Carolina Hinestrosa is at the National Breast Cancer Coalition Fund 1101 17th Street, NW, Suite 1300 Washington, DC 20036, USA.
2. Key Dickersin is at the Department of Epidemiology Johns Hopkins Bloomberg School of Public Health 615 Norht Wolfe Street, Mailroom 5010, Baltimore, Maryland, 21205 USA.
3. Musa Mayer is at www.AdvancedBC.0rg, 250 West 82nd Street, Apt. 42, New York, New York, 10024, USA.
4. Karin Noss is at the Virginia Breast Cancer Foundation 5004 Monument Ave, Suite 102 Richmond, Virginia 23230, USA.
5. Dennis Slamon is at the Division of Hematology-Oncology, Department of Medicine, UCLA Shcool of Medicine, 11-93 Louis Factor building, 10833 Le Conte Avenue, Los Angeles, California 900-5, USA.
6. George Sledge is at the Indiana University Medical Center, Indiana Cancer Pavilion, Room 473 535 Barnhill Drvive, Indianapolis, Indiana, 46202, USA.

Correspondence to: M. Carolina Hinestrosa¹ Email: chinestrosa@stopbreastcancer.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.